Ivabradine Tablet, Film Coated
Product Images NDC 50742-362

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 50742-362). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 01)

Chemical structure of Ivabradine hydrochloride, showing its molecular arrangement with methoxy groups and a fused ring system, consistent with the active ingredient Ivabradine.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 02)

A forest plot chart illustrating fold changes and 90% confidence intervals for pharmacokinetic measures (Cmax and AUC) of ivabradine when co-administered with various drugs, including strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, and other agents. The x-axis shows fold change relative to ivabradine alone, and recommendations are listed to avoid use or no dose adjustment based on interaction impact.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 03)

A line graph showing the proportion of subjects with heart failure hospitalization or cardiovascular death over 36 months, comparing Corlanor and placebo groups. The x-axis represents time from randomization in months, and the y-axis shows the proportion percentage. Tabulated subject counts at risk for each group are included below the graph.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 04)

A forest plot comparing Ivabradine Tablets versus Placebo across various population subgroups. The chart lists subgroups by age, sex, race, cause of heart failure, weight quartile, baseline heart rate quartile, NYHA Class, baseline LV ejection fraction, baseline beta blocker and aldosterone antagonist use, diabetes, and hypertension. It shows hazard ratios with 95% confidence intervals, indicating the relative effect favors Ivabradine or placebo for these groups.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 05)

FDA Label Image

Ivabradine Tablets, 5 mg (Bottle Label 60 count)

Label for Ivabradine Tablets 5 mg, oral film-coated tablets manufactured for Ingenus Pharmaceuticals, LLC. The label indicates a package size of 60 tablets, with storage instructions and prescription-only status. It includes dosing information reference and a URL for medication guides.*

FDA Label Image

Ivabradine Tablets, 7.5 mg (Bottle Label-60 count)

Label for Ivabradine 7.5 mg film-coated tablets manufactured for Ingenus Pharmaceuticals, LLC. The label includes a barcode, NDC 50742-363-60, and states the package contains 60 tablets. Storage instructions and usage notes are printed, with a pharmacist guidance box and a link to medication guides.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 92 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.